Data Informing Treatment Decisions and Strategies in HER2+ Breast Cancer | Supplements and Featured Publications
Supported in part by Daiichi Sankyo. Content produced and independently developed by OncLive.
T-DXd Plus Pertuzumab Could Add to Antibody-Drug Conjugate Arsenal in HER2+ Breast Cancer
June 18, 2025
Article
Sarah Sammons, MD, discusses data with T-DXd in frontline HER2-positive breast cancer and other ADCs in the breast cancer space.
T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD
June 11, 2025
Podcast
Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting
T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer
June 06, 2025
Article
Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.
Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer
June 06, 2025
Video
Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.
Dr Sammons on the Significance of DESTINY-Breast09 for the HER2+ Breast Cancer Treatment Paradigm
June 05, 2025
Video
Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.
Dr O’Meara on the Evolving Role of ADCs in HER2+ Breast Cancer
June 04, 2025
Video
Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.
First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer
June 02, 2025
Article
Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.
Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management
May 19, 2025
Video
Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.
Dr Tarantino on the Potential Relevance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer
May 16, 2025
Video
Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.